Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 17/01/2023

    Endogenous molecule protects from life-threatening complications after stem-cell transplantation

    Acute Graft-versus-host disease (GvHD) is a life-threatening complication after leukemia treatment with allogeneic stem cell transplantation i.e. the transplantation of cells from another person. GvHD occurs when the transplanted immune cells are overly active and damage the receiving patient's healthy tissue. Researchers found that an endogenous molecule can mitigate this misdirected immune response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/koerpereigenes-molekuel-schuetzt-vor-lebensbedrohlichen-komplikationen-nach-stammzelltransplantation
  • Press release - 17/01/2023

    Sugar-based inhibitors disarm the pathogen Pseudomonas aeruginosa

    The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections. Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/zuckerbasierte-inhibitoren-entwaffnen-den-krankheitserreger-pseudomonas-aeruginosa
  • Press release - 11/01/2023

    Newly discovered surface structures may affect immune function

    Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
  • Funding

    IHI call 3

    Funding programme, Funded by: European Union, Submission deadline: 15/03/2023
    https://www.gesundheitsindustrie-bw.de/en/database/funding/ihi-call-3
  • Press release - 20/12/2022

    Rapid Evolution of Spermatogenesis

    Heidelberg scientists decode the genetic foundations of rapid testicle evolution in mammals and humans. Evolutionary pressure across male mammals to guarantee the procreation of their own offspring led to a rapid evolution of the testicle.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rapid-evolution-spermatogenesis
  • Press release - 20/12/2022

    New approach prevents rejection of transplanted organs

    Inhibition of a protein complex in cells of the immune system prevents rejection of transplanted organs – this has been shown in a study by immunologists from the University of Konstanz, the Biotechnology Institute Thurgau (BITg) and Chongqing Cancer University Hospital.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevents-rejection-transplanted-organs
  • Funding

    EU4Health Programme (EU4H) – Action Grants 2022

    Funding programme, Funded by: European Union, Submission deadline: 21/02/2023
    https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme-eu4h-action-grants-2022
  • Press release - 01/12/2022

    Development of the immune system before and after birth

    The newborn's immune system is suddenly confronted with microorganisms, food and numerous environmental influences at birth. How do the baby's immune cells prepare for this moment during pregnancy and birth? How do external influences shape the immune system immediately after birth? And what influence does an event like a premature birth have?

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/development-immune-system-and-after-birth
  • Press release - 29/11/2022

    Prototype funding for two Konstanz projects

    Chemical building blocks from plastic waste; Reducing the risk of falls using virtual orientation aids: Konstanz chemists Manuel Häußler and Lukas Odenwald as well as sport scientist Lorenz Assländer receive Baden-Württemberg prototype funding for their transfer projects "Waste2DCA" and "Augmented Balance".

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/doppelter-erfolg-der-prototypenfoerderung
  • Start-up Actimi GmbH - 23/11/2022 The photo shows a body scale and the user interface of the app on the tablet. Furthermore, a bag and the ECG measuring device can be seen.

    Real-time telemonitoring of heart failure

    Improved quality of life for patients and lower costs for health insurers: these are the advantages of telemonitoring patients with advanced heart failure. The Stuttgart-based start-up Actimi offers an all-in-one platform for those who treat and those who suffer from the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/real-time-telemonitoring-heart-failure
  • Press release - 17/11/2022

    New target for Alzheimer's therapies found

    DZNE researchers discover link between the protein medin and Alzheimer's disease. The protein medin is deposited in the blood vessels of the brains of Alzheimer's patients along with the protein amyloid-β. DZNE Researchers have discovered this so-called co-aggregation. They have now published their observation in the renowned journal Nature.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-target-alzheimers-therapies-found
  • Press release - 09/11/2022

    New Molecular Microscopy Uncovers how Breast Cancer Spreads

    Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
  • Press release - 02/11/2022

    The guardian of the (epi-)genome

    Toxicologists from the University of Konstanz have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/guardian-epi-genome
  • Press release - 20/10/2022

    Cytoskeleton acts as cells’ bouncer for bacteria

    Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
  • Press release - 19/10/2022

    Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients

    Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
  • Press release - 19/10/2022

    Molecular structure of one of the most important receptors in the immune system unraveled

    Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
  • Press release - 05/10/2022

    Second Stem Cell Type Discovered in Mouse Brain

    In the brain of adult mammals neural stem cells ensure that new nerve cells, i.e. neurons, are constantly formed. This process, known as adult neurogenesis, helps mice maintain their sense of smell. A research team led by Dr Francesca Ciccolini at the Interdisciplinary Center for Neurosciences (IZN) of Heidelberg University recently discovered a second stem cell population in the mouse brain.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/zweiter-stammzelltyp-im-maeusehirn-entdeckt
  • Press release - 01/09/2022

    Personalised antibiotic treatment strategies for tuberculosis patients

    Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/personalisierte-antibiotika-behandlungsstrategie-bei-tuberkulose-erkrankten
  • Press release - 03/06/2022

    Deep Learning helps improve gene therapies and antiviral drugs

    The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/deep-learning-helps-improve-gene-therapies-and-antiviral-drugs
  • Press release - 12/05/2022

    New hope for broad spectrum viral entry inhibitors – Negatively charged polymer proves effective against a wide range of viruses

    While broad-spectrum antibiotics can offer protection against a wide variety of bacteria, there are currently no analogous clinically available broad-spectrum antiviral agents that can act on several different viruses. An international research team has now shown that polystyrene sulfonate (PSS), a negatively charged polymer, has the potential to be used in the prevention of viral infections – not only in the fight against the SARS-CoV-2 and cold…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-hope-broad-spectrum-viral-entry-inhibitors-negatively-charged-polymer-proves-effective-against-wide-range-viruses
  • Press release - 28/04/2022

    Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors

    Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
  • Press release - 25/04/2022

    Reprogrammed macrophages promote spread of breast cancer

    Metastatic breast cancer cells abuse macrophages, a type of immune cell, to promote the settlement of cancer metastases in the lungs. The reprogrammed macrophages stimulate blood vessel cells to secrete a cocktail of metastasis-promoting proteins that are part of the so-called metastatic niche.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-macrophages-promote-spread-breast-cancer
  • Peptide-based COVID-19 vaccine - 21/04/2022 A 96-well analysis plate with depressions of varying darkness is shown, held up by two gloved hands.

    CoVac-1: T-cell activator against COVID-19

    Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.

    https://www.gesundheitsindustrie-bw.de/en/article/news/covac-1-t-cell-activator-against-covid-19
  • Press release - 14/03/2022

    Do gut bacteria influence treatment success of CAR-T cell therapies?

    Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
  • Press release - 03/03/2022

    Identifying Alzheimer's risks – as early as 17 years before diagnosis

    In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis

Page 1 / 24

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 24
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search